The Role of Nurses in Caring for Patients with Dermatologic Side Effects from EGFR Inhibitors
Keywords:
the role of nurses, caring for patients with dermatologic side effects, EGFR inhibitorsAbstract
EGFR Inhibitors are used in the treatment of lung cancer patients with EGFR gene mutations. These drugs exhibit highly specific effects, leading to enhanced treatment efficacy. However, they also cause side effects in various systems, particularly the skin. These side effects can lead to a loss of self-image, discomfort, and reduced quality of life for patients. Therefore, Nurses, who play a crucial role in caring for these patients, must have the necessary knowledge and apply evidence-based practices to their caregiving roles. This article discusses the pathophysiology and dermatologic side effects of EGFR inhibitors, guidelines for prevention and treatment, as well as the nurse’s role in assessing and advising patients on self-care regarding these dermatologic side effects.
References
American Cancer Society. Targeted drug therapy for non-small cell lung cancer [Internet]. ACS; [cited 2024 January 20]. Available from: https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html
Lucia STANCULEANU D, Zob D, Catalina TOMA O, Georgescu B, Papagheorghe L, Ioana MIHAILA R, et al. Cutaneous toxicities of molecular targeted therapies. Maedica (Bucur) [Internet]. 2017 Jan [cited 2024 Sep 1];12:48. Available from:/pmc/articles/ PMC5574072/
Diamanti O, Zacheo TM, Lando C, Magro C, Pauletti G, Zemella E, et al. Pilot study: Nurses’ role in management of cutaneous toxicity in patients with targeted therapies anti EGFR-Is’ treatment. Annals of Oncology [Internet]. 2018 Oct 1 [cited 2024 Sep 1];29:viii697. Available from: http://www.annalsofoncology.org/article/S0923753419488601/fulltext
Klungsaeng S, Senggunprai L. Protein serine-threonine kinase as drug target in cancer treatment. Srinagarind Med J.2020;35:488-95.
Zubair T, Bandyopadhyay D. Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. Int J Mol Sci.2023;24:1-9.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol [Internet]. 2015 [cited 2024 Sep 1];72:203–18. Available from: https://pubmed.ncbi.nlm. nih.gov/25592338/
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol [Internet]. 2014 [cited 2024 Sep 1];71:217.e1-217.e11. Available from: https://pubmed.ncbi.nlm.nih.gov/ 25037801/
Lupu I, Voiculescu VM, Bacalbasa N, Prie BE, Cojocaru I, Giurcaneanu C. Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors. J Med Life [Internet]. 2015 [cited 2024 Sep 1];8(Spec Issue):57. Available from: /pmc/articles/PMC4564034/
Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol [Internet]. 2012 [cited 2024 Sep 1];67:400–8. Available from: https://www.ncbi. nlm.nih.gov/books/NBK109674/
Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K. Management of egfr tki–induced dermatologic adverse events. Current Oncology [Internet]. 2015 [cited 2024 Sep 1];22:123. Available from: /pmc/articles/PMC4399609/
Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care. Nurs Clin North Am [Internet]. 2017 Mar 1 [cited 2024 Sep 1];52:83. Available from:/pmc/articles/PMC 5645079/
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). (No Title). 2017 Jan 3.
Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol [Internet]. 2016 Apr 1 [cited 2024 Sep 1];46:291. Available from: /pmc/articles/PMC4886131/
Huynh Dagher S, Blom A, Chabanol H, Funck-Brentano E. Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management. Int J Womens Dermatol [Internet]. 2021 Dec 1 [cited 2024 Sep 1]; 7(5Part A): 615–24. Available from: https://pubmed.ncbi.nlm.nih.gov/35024416/
Williams LA, Ginex PK, Ebanks GL, Ganstwig K, Ciccolini K, Kwong BY, et al. ONS GuidelinesTM for cancer treatment-related skin toxicity. Oncol Nurs Forum [Internet]. 2020 [cited 2024 Sep 1];47:539–56. Available from: https://pubmed.ncbi.nlm.nih.gov/ 32830806/
Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. https://doi.org/101200/EDBK_289911 [Internet]. 2020 May 18 [cited 2024 Sep 1];485–500. Available from: https://ascopubs.org/doi/10.1200/EDBK_289911
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Thailand's National Cancer Institute Foundation
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
